Evidence map›Paper›PMID 33125345›Full record

ArticleAging2020

MerTK, a risk factor for NASH fibrosis.

Xiaobo Wang, Bishuang Cai

Open access · greenAbstract readEditorialComment
In one paragraph

Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 82% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Insulin receptor responsiveness governs TGFβ-induced hepatic stellate cell activation: Insulin resistance instigates liver fibrosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Xiaobo WangDepartment of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA.
Bishuang CaiDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Columbia University Irving Medical Center · USIcahn School of Medicine at Mount Sinai · US

Funding

MerTK in NASH-related liver fibrosisR00DK115778 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CAI, BISHUANG · 2020 to 2022
$747k
NIDDK NIH HHS R00 DK115778
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Non-alcoholic Fatty Liver Diseasec-Mer Tyrosine KinaseFibrosisHumansLiver CirrhosisRisk Factorsc-Mer Tyrosine KinaseMERTK protein, humanADAM17GWASliver fibrosisMerTKNASH

Identifiers

PMID33125345
PMCPMC7655196
OpenAlexW3095600528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.